The fiscal year ending March 2026 recorded revenues of approximately \u00a5273.7 billion, operating profit of \u00a523.1 billion, and net income of \u00a55.2 billion, representing an increase compared to the same period last year. Revenue exceeded the prior year’s figure, and profits showed substantial growth.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-05-14","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4553-20260514-02.pdf","jir_short_summary":"The fiscal year ending March 2026 recorded revenues of approximately \u00a5273.7 billion, operating profit of \u00a523.1 billion, and net income of \u00a55.2 billion, representing an increase compared to the same period last year. Revenue exceeded the prior year's figure, and profits showed substantial growth.","jir_summary":"### Summary of Financial Results\nTowa Pharmaceutical's fiscal year ending March 2026 reported revenues of approximately \u00a5273.7 billion (YoY +5.4%), operating income of \u00a523.1 billion (YoY -0.6%), and net income of \u00a55.2 billion (YoY -72.3%). While revenue increased compared to the previous year, net income decreased significantly. The revenue growth was mainly driven by increased sales of pharmaceuticals domestically and internationally. Although the business scale expanded, the decline in net income is attributed to some increased costs and special losses.\n\n### Future Outlook and Investor Impact\nThe company aims to continue increasing revenues while focusing on cost management and efficiency improvements to enhance profitability. For investors, sustaining revenue growth and working towards profit improvement are key priorities. Progress in research and development expenses and cost reduction initiatives is expected to improve future profitability.","jir_financial_highlights":"Revenue: \u00a5273.7 billion (+5.4\uff05)\nOperating Income: \u00a523.1 billion (-0.6\uff05)\nNet Income: \u00a55.2 billion (-72.3\uff05)","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #EarningsReport, #JapaneseStocks","jir_key_figures":"Revenue: \u00a5273.7 billion (YoY +5.4%)\nOperating Income: \u00a523.1 billion (YoY -0.6%)\nNet Income: \u00a55.2 billion (YoY -72.3%)","jir_meta_title":"\u3010Towa Pharmaceutical\u3011Fiscal Year Ending March 2026 Financial Results | Revenue \u00a5273.7 Billion (+5.4%)","jir_meta_description":"Towa Pharmaceutical's fiscal year ending March 2026 reported revenues of approximately \u00a5273.7 billion and rising profits. An overview of future business prospects and key investment points.","jir_og_title":"\u3010Towa Pharmaceutical\u3011Fiscal Year Ending March 2026 Financial Results | Revenue \u00a5273.7 Billion (+5.4%)","jir_og_description":"An overview of Towa Pharmaceutical\u2019s financial results and future outlook. Initiatives for revenue growth and profit improvement are introduced for investors.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-50975","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n